
CLAIMS

What is claimed is:

1. A compound of the formula (I):



(I)

wherein:

n is 1, 2 or 3;

R_1 is selected from the group consisting of hydrogen, methyl, fluoromethyl, ethyl, 2-fluoroethyl and propyl;


R_2 is selected from the group consisting of hydrogen, methyl, fluoromethyl, ethyl, 2-fluoroethyl, propyl, 1,1-difluoropropyl, methoxymethyl and 2-fluoroethoxymethyl;

R_3 and R_4 are the same or different and independently of each other selected from the group consisting of $(C_1\text{-}C_4)$alkyl, phenyl and benzyl; or

R_3 and R_4 taken together with the carbon atom to which they are attached form a substituted or unsubstituted $C_3\text{-}C_7$ carbocyclic ring; and

R_5 and R_6 are the same or different and independently of each other selected from the group consisting of hydrogen, halogen, $(C_1\text{-}C_4)$alkyl and $(C_1\text{-}C_4)$alkoxy.

2. The compound according to claim 1, which is having the formula II:



(II)

wherein:

R_1 is selected from the group consisting of hydrogen, methyl and ethyl;

R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl and 1,1-difluoropropyl;

R_3 and R_4 are the same or different and independently of each other selected from the group consisting of methyl, ethyl and propyl; or

R_3 and R_4 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl or cyclopentyl ring; and

R_5 and R_6 are the same or different and independently of each other selected from the group consisting of hydrogen, fluorine, bromine, methyl and ethyl.

3. The compound according to claim 2, wherein:

R_1 is hydrogen or ethyl;

R_2 is hydrogen or methyl;

R_3 and R_4 are each methyl; and

R_5 is hydrogen or methyl;

R_6 is hydrogen or methyl.

4. The compound according to claim 2, which is selected from the group consisting of:

(S)-2-(1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(6-bromo-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(6-chloro-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(6-fluoro-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(1,1,6-trimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;


(S)-2-(1,1-dimethyl-indan-5-yloxymethyl)-6-ethyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-5-(1,1-difluoro-propyl)-2-(1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one; and

(S)-2-(1,1-dimethyl-indan-5-yloxymethyl)-5-methyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one.

5. The compound according to claim 2, which is selected from the group consisting of:
(S)-2-(6-fluoro-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;
(S)-2-(6-bromo-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;
(S)-2-(1,1,6-trimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one; and
(S)-2-(6-chloro-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one..

6. The compound according to claim 1, which is having the formula III:



(III)


wherein:
R_1 is selected from the group consisting of hydrogen, methyl and ethyl;
R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl and 1,1-difluoropropyl;
R_3 and R_4 are the same or different and independently of each other selected from the group consisting of methyl, ethyl and propyl; or
R_3 and R_4 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl or cyclopentyl ring; and
R_5 and R_6 are the same or different and independently of each other selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl and ethyl.

7. The compound according to claim 6, wherein:
R_1 is hydrogen or ethyl;
R_2 is hydrogen, methyl or 1,1-difluoropropyl;
R_3 and R_4 are each methyl; and
R_5 is hydrogen, fluorine, or methyl;

R_6 is hydrogen or methyl.

8. The compound according to claim 6, which is selected from the group consisting of:
(S)-2-(5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;
(S)-2-(5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl)-6-ethyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one
(S)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one; and
(S)-5-(1,1-difluoro-propyl)-2-(5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one.

9. A compound of the formula IV:



(IV)

wherein:
R_1 is selected from the group consisting of hydrogen, methyl and ethyl;
R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl and 1,1-difluoropropyl;
R_3 and R_4 are the same or different and independently of each other selected from the group consisting of methyl, ethyl and propyl; or
R_3 and R_4 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl or cyclopentyl ring; and
R_5 and R_6 are the same or different and independently of each other selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl and ethyl.

10. The compound according to claim 9, wherein:
R_1 is hydrogen;
R_2 is hydrogen;
R_3 and R_4 are each methyl; and

R_5 is hydrogen, fluorine or methyl;
R_6 is hydrogen or methyl.

11. The compound according to claim 9, which is:
(S)-2-(5,5-dimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one.


12. A pharmaceutical composition comprising one or more compounds of claims 1 to 11 in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.

13. Use of a compound of any of claims 1 to 11 or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition, which compound is capable of modulating one or more metabotropic glutamate receptor functions for treating neurological or psychiatric disorders.

14. Use of a compound of any of claims 1 to 11 or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition, which compound is capable of modulating one or more metabotropic glutamate receptor functions for treating anxiety, migraine, schizophrenia, cognitive disorders, epilepsy and pain.

What is claimed is:

1. A compound of the formula (I):



(I)

wherein:

n is 1, 2 or 3;

R_1 is selected from the group consisting of hydrogen, methyl, fluoromethyl, ethyl, 2-fluoroethyl and propyl;


R_2 is selected from the group consisting of hydrogen, methyl, fluoromethyl, ethyl, 2-fluoroethyl, propyl, 1,1-difluoropropyl, methoxymethyl and 2-fluoroethoxymethyl;

R_3 and R_4 are the same or different and independently of each other selected from the group consisting of (C_1-C_4)alkyl, phenyl and benzyl; or

R_3 and R_4 taken together with the carbon atom to which they are attached form a substituted or unsubstituted C_3-C_7 carbocyclic ring; and

R_5 and R_6 are the same or different and independently of each other selected from the group consisting of hydrogen, halogen, (C_1-C_4)alkyl and (C_1-C_4)alkoxy.

2. The compound according to claim 1, which is having the formula II:



(II)

wherein:

R_1 is selected from the group consisting of hydrogen, methyl and ethyl;

R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl and 1,1-difluoropropyl;

R_3 and R_4 are the same or different and independently of each other selected from the group consisting of methyl, ethyl and propyl; or

R_3 and R_4 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl or cyclopentyl ring; and

R_5 and R_6 are the same or different and independently of each other selected from the group consisting of hydrogen, fluorine, bromine, methyl and ethyl.

3. The compound according to claim 2, wherein:

R_1 is hydrogen or ethyl;

R_2 is hydrogen or methyl;

R_3 and R_4 are each methyl; and

R_5 is hydrogen or methyl;

R_6 is hydrogen or methyl.

4. The compound according to claim 2, which is selected from the group consisting of:

(S)-2-(1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(6-bromo-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(6-chloro-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(6-fluoro-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(1,1,6-trimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(1,1-dimethyl-indan-5-yloxymethyl)-6-ethyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-5-(1,1-difluoro-propyl)-2-(1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one; and

(S)-2-(1,1-dimethyl-indan-5-yloxymethyl)-5-methyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one.

5. The compound according to claim 2, which is selected from the group consisting of:


(S)-2-(6-fluoro-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(6-bromo-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(1,1,6-trimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one; and

(S)-2-(6-chloro-1,1-dimethyl-indan-5-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one.

6. The compound according to claim 1, which is having the formula III:



(III)

wherein:

R_1 is selected from the group consisting of hydrogen, methyl and ethyl;

R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl and 1,1-difluoropropyl;

R_3 and R_4 are the same or different and independently of each other selected from the group consisting of methyl, ethyl and propyl; or

R_3 and R_4 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl or cyclopentyl ring; and

R_5 and R_6 are the same or different and independently of each other selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl and ethyl.

7. The compound according to claim 6, wherein:

R_1 is hydrogen or ethyl;

R_2 is hydrogen, methyl or 1,1-difluoropropyl;

R_3 and R_4 are each methyl; and

R_5 is hydrogen, fluorine, or methyl;

R_6 is hydrogen or methyl.

8. The compound according to claim 6, which is selected from the group consisting of:


(S)-2-(5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one;

(S)-2-(5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl)-6-ethyl-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one

(S)-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one; and

(S)-5-(1,1-difluoro-propyl)-2-(5,5-dimethyl-5,6,7,8-tetrahydro-naphthalen-2-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one.

9. The compound according to claim 1, which is of the formula IV:



(IV)

wherein:

R_1 is selected from the group consisting of hydrogen, methyl and ethyl;

R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl and 1,1-difluoropropyl;

R_3 and R_4 are the same or different and independently of each other selected from the group consisting of methyl, ethyl and propyl; or

R_3 and R_4 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl or cyclopentyl ring; and

R_5 and R_6 are the same or different and independently of each other selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl and ethyl.

10. The compound according to claim 9, wherein:

R_1 is hydrogen;

R_2 is hydrogen;

R_3 and R_4 are each methyl; and

R_5 is hydrogen, fluorine or methyl;

R_6 is hydrogen or methyl.

11. The compound according to claim 9, which is:

(S)-2-(5,5-dimethyl-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-yloxymethyl)-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-one.

12. A pharmaceutical composition comprising one or more compounds of claims 1 to 11 in combination with one or more pharmaceutically acceptable carriers, diluents or excipients.
13. A compound according to any of claims 1 to 11 or a pharmaceutically acceptable salt thereof for use in treating neurological or psychiatric disorders.
14. A compound according to any of claims 1 to 11 or a pharmaceutically acceptable salt thereof for use in treating anxiety, migraine, schizophrenia, cognitive disorders, epilepsy and pain.